PhysIQ announced today that the National Institutes of Health (NIH) entered into Phase II of a contract for its AI-based COVID-19 biomarker.
A Purdue University-affiliated artificial intelligence company, PhysIQ’s AI-based COVID-19 digital biomarker is being developed to address the rapid decompensation of high-risk COVID-19 patients, according to a news release.
PhysIQ’s technology’s cloud platform continuously collects and processes data from any wearable biosensor. In this case, the platform seeks out biomarkers to determine if a person infected with COVID-19 is experiencing a worsening in their condition.
Instead of using measurements such as temperature and pulse oximetry, PhysIQ’s platform offers multi-parameter vital signs and physiological features which establish a targeted biomarker (COVID-19 Decompensation Index — CDI) for worsening coronavirus-caused condition.
The contract option, exercised by the National Canc…